“By introducing never before seen self-sustaining consortia of beneficial bacteria we aim to rebalance the microbiome…“
A disruption of the gut microbiota can result in many different conditions including obesity and malnutrition, infections by the pathogenic bacterium Clostridium difficile, and chronic inflammatory diseases such as allergies, diabetes, plaque psoriasis and inflammatory bowel disease. Also, aging related diseases like Parkinson’s disease and Alzheimer’s disease have been linked to dysbiosis of the gut microbiome. Gusto is developing novel live biotherapeutic formulations in the context of systematically addressing this wide variety of complex conditions where microbiome community interactions play a significant role. Our formulations of bacteria are precisely designed to restore missing functionalities and achieve targeted immune modulation and optimization of metabolic pathways.
Gusto’s LBP efforts focus on the gut microbiome and the body’s immune response with two programs that have contrasting objectives:
Our IBD program seeks to change a pro-inflammatory dysbiotic gut microbiome to a healthy one, thereby restoring an overactive immune system and overcoming problems with the inflamed lining of the intestine. Multiple bacterial strains within our lead candidate, GUT-108, provide critical functions that are missing from the pro-inflammatory microbiome of IBD patients. These functions include synthesis of beneficial metabolites to support epithelial health and immune homeostasis, the conversion of bile acids, and the control of pathogenic bacteria that thrive in the inflamed GI tract. In collaboration with the Crohn’s and Colitis Foundation, GUT-108 is being validated in animal studies to delay relapse of IBD after treatment with immune suppressing drugs.
Gusto’s live biotherapeutic for immuno-oncology is engineered to modulate the gut microbiome of cancer patients that are non-responsive to immune checkpoint inhibitors, like KEYTRUDA®, by inciting a more active immune system that overcomes immune dormancy in the tumor environment. Our lead candidate, GUT-115, is being developed as an adjuvant therapy to immune checkpoint inhibitors, and seeks to provide critical functions to awaken the immune system and increase levels of tumor infiltrating immune cells.